India has an estimated 101 million people with type 2 diabetesand another 136 million with pre-diabetes (ICMR-INDIAB, 2023). A significant fraction of them also live with overweight or obesity. Traditionally, doctors picked one to treat first — usually diabetes — and dealt with the weight separately, often unsuccessfully.

GLP-1 receptor agonists changed that decision tree.

What GLP-1 does for blood sugar

GLP-1 lowers blood glucose through three mechanisms simultaneously:

  • Glucose-dependent insulin release.When blood sugar rises after a meal, GLP-1 amplifies the pancreas's insulin response. When sugar is normal, it doesn't — so it doesn't cause hypoglycaemia by itself.
  • Suppresses glucagon. Glucagon tells the liver to release stored glucose. GLP-1 turns that down.
  • Slows gastric emptying.Food enters the bloodstream as glucose more gradually — flattening the post-meal spike.
HbA1c reduction
−1.5 to −2.0%
Average HbA1c drop on semaglutide or tirzepatide at 6 months in real-world cohorts of Indian patients.

Why this is a big deal in India specifically

The default Indian type-2 diabetes regimen for the last 20 years has been: metformin → add sulfonylurea → add insulin. That ladder has two problems:

  • Sulfonylureas and insulin cause weight gain.For patients who are already overweight, the medication makes the underlying driver worse.
  • Hypoglycaemia risk.Both classes can drop blood sugar too low, which is dangerous — especially in elderly patients.

GLP-1 medications cause weight loss, not weight gain, and don't cause hypoglycaemia on their own. Indian and international guidelines now recommend them as a second-line option after metformin for patients with diabetes + obesity.

The cardiovascular benefit

Several large trials (LEADER, SUSTAIN-6, REWIND) have shown that GLP-1 medications reduce major cardiovascular events — heart attack, stroke, cardiovascular death — in patients with type 2 diabetes who have either established cardiovascular disease or are at high risk. The relative-risk reduction is roughly 12–14%.

For Indian patients, who are at elevated cardiac risk at younger ages, this benefit is particularly meaningful.

When GLP-1 isn't first-line

Despite the strength of the data, GLP-1 isn't the right starting point for every Indian diabetic patient. We don't typically start with it when:

  • HbA1c is mildly elevated (e.g. 6.5–7.0%). Metformin + lifestyle often controls this without injection.
  • The patient is normal-weight. The weight-loss effect that makes GLP-1 powerful in obesity isn't needed; SGLT-2 inhibitors or DPP-4 inhibitors are often better choices.
  • Severe gastrointestinal disease. Active gastroparesis, severe IBS, or post-bariatric surgery patients need a different approach.
  • Personal or family history of medullary thyroid carcinoma or MEN-2. Hard contraindication.

The combination question: GLP-1 + other diabetes drugs

Most patients on GLP-1 for diabetes also stay on metformin — the two work well together. Common combinations we see:

  • Metformin + GLP-1 (semaglutide or tirzepatide) for most.
  • Metformin + SGLT-2 + GLP-1 in patients with both diabetes and heart failure.
  • Reduce or stop sulfonylureas if HbA1c is well-controlled, to avoid hypoglycaemia.
  • Reduce insulin dose by ~20% when starting GLP-1 to prevent lows.

These adjustments matter, which is why a real doctor consultation is the only safe way to start GLP-1 when you're already on diabetes medication.

What success looks like

At 6 months on GLP-1, a typical patient with diabetes + obesity will see:

  • HbA1c down by 1.5–2.0 percentage points.
  • Weight down by 8–12% of starting body weight.
  • Lower BP, often reduced antihypertensive dose.
  • Improved lipid profile (triglycerides drop, HDL improves).
  • Frequently, ability to come off sulfonylureas or reduce insulin.

That's not a hypothetical — that's the outcome published in dozens of real-world Indian cohorts over the last two years.